US Rx Spending Growth Projected To Stay Modest; Will Political Debate Change?
Executive Summary
The latest update by the US Centers for Medicare & Medicaid Services to national health care spending forecasts continues to put prescription drugs in line with – or even slightly below – overall growth rates. Of course, that likely won’t change the political attention to the issue in 2022.
You may also be interested in...
Vaccines For Uninsured Adults Initiative Proposed In Biden’s Federal Budget For 2023
Biden budget proposal also addresses consolidating all Medicare coverage for vaccines under Part B, providing Medicare and Medicaid 'explicit' authority to cover vaccines approved under emergency use authorizations without cost sharing, and increasing 340B spending on program oversight.
Senate Democrats Running Out Of Time On Drug Pricing Reform
Is less ambitious drug pricing reform better than nothing? Senate Finance Committee Chair Wyden still pushing for a version of the most aggressive policy, direct government price negotiation.
Copay Coupons, Lower Utilization Reduced Out-Of-Pocket Spending On Retail Drugs In 2020
Overall drug spending rose 3% to $348bn in 2020, according to the latest US National Health Expenditures report. COVID-19 lowered drug utilization and spending, but not as much as it impacted health care services.